Effects of insulin-like growth factor on linear growth, head circumference, and body fat in patients with Laron-type dwarfism

Lancet. 1992 May 23;339(8804):1258-61. doi: 10.1016/0140-6736(92)91594-x.


Patients with Laron-type dwarfism are clinically indistinguishable from those with isolated growth hormone (GH) deficiency, yet have high circulating GH concentrations associated with an inability to generate endogenous insulin-like growth factor I (IGF-I). Biosynthetic IGF-I was administered subcutaneously once daily for 3 to 10 months to 5 children with Laron-type dwarfism aged 3.3 to 14.5 years. There was a rapid stimulation of linear growth in body limbs, with a striking increase in head circumference, increased body weight, and a reduction in subcutaneous fat. Administration of IGF-I to patients with Laron-type dwarfism seems to have a beneficial effect on growth similar to that observed with long-term administration of GH in children with GH deficiency.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adipose Tissue
  • Adolescent
  • Anthropometry
  • Cephalometry
  • Child
  • Child, Preschool
  • Dwarfism, Pituitary / blood
  • Dwarfism, Pituitary / drug therapy*
  • Dwarfism, Pituitary / physiopathology
  • Female
  • Growth Hormone / blood
  • Growth* / drug effects
  • Humans
  • Insulin-Like Growth Factor I / therapeutic use*
  • Male
  • Recombinant Proteins / therapeutic use


  • Recombinant Proteins
  • Insulin-Like Growth Factor I
  • Growth Hormone